Kinetoplastida: new therapeutic strategies

Area of Science:

• Neglected tropical diseases
• Drug discovery and development
• Parasitic infections

Background:

• Visceral leishmaniasis (VL) chemotherapy has advanced with new drug formulations and miltefosine.
• Human African trypanosomiasis (HAT), Chagas disease, and cutaneous leishmaniases treatments show limited progress.
• Existing HAT treatments focus on combinations like eflornithine with melarsoprol or nifurtimox, with limited options for late-stage disease.

Purpose of the Study:

• To review the current status of drug development for leishmaniases and trypanosomiases.
• To identify challenges and opportunities in discovering new treatments for neglected parasitic diseases.
• To highlight the importance of integrating scientific disciplines and industry collaboration for effective drug discovery.

Main Methods:

• Review of current therapeutic strategies and drug development pipelines for VL, HAT, and Chagas disease.
• Analysis of advancements in understanding pathogen genomics and target validation.
• Examination of the role of medicinal chemistry, pharmacokinetics, and project management in drug development.

Main Results:

• Significant improvements in VL treatment, contrasting with slow progress in HAT and Chagas disease.
• Development of novel compounds like parfuramidine for early-stage HAT.
• Identification of validated biochemical targets (sterol biosynthesis methylases, cysteine proteases) for Chagas disease drug development.

Conclusions:

• Genome sequencing and target validation methods are crucial for discovering new anti-parasitic drugs.
• Integration of medicinal chemistry, pharmacokinetics, and industry partnerships is essential for therapeutic progress.
• New funding sources and product development partnerships offer hope for overcoming financial constraints in neglected disease drug development.